keyword
MENU ▼
Read by QxMD icon Read
search

Angiotensin inhibitor

keyword
https://www.readbyqxmd.com/read/28346238/management-of-hypertension-in-2017-targets-and-therapies
#1
Monica Ahluwalia, Sripal Bangalore
PURPOSE OF REVIEW: Approximately one-fourth of the adult population is diagnosed with hypertension, which has been associated with increased cardiovascular morbidity and mortality including cardiovascular death, myocardial infarction, heart failure and stroke. Early detection and treatment is a key and can lead to a significant reduction in cardiovascular morbidity and mortality. RECENT FINDINGS: In this review, we discuss the management and treatment strategies in patients with hypertension in the current era...
March 24, 2017: Current Opinion in Cardiology
https://www.readbyqxmd.com/read/28345667/the-toxicity-of-angiotensin-converting-enzyme-inhibitors-to-larvae-of-the-disease-vectors-aedes-aegypti-and-anopheles-gambiae
#2
Zatul-'Iffah Abu Hasan, Helen Williams, Nur M Ismail, Hidayatulfathi Othman, Gyles E Cozier, K Ravi Acharya, R Elwyn Isaac
The control of mosquitoes is threatened by the appearance of insecticide resistance and therefore new control chemicals are urgently required. Here we show that inhibitors of mosquito peptidyl dipeptidase, a peptidase related to mammalian angiotensin-converting enzyme (ACE), are insecticidal to larvae of the mosquitoes, Aedes aegypti and Anopheles gambiae. ACE inhibitors (captopril, fosinopril and fosinoprilat) and two peptides (trypsin-modulating oostatic factor/TMOF and a bradykinin-potentiating peptide, BPP-12b) were all inhibitors of the larval ACE activity of both mosquitoes...
March 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28345319/vascular-cell-adhesion-molecule-1-intercellular-adhesion-molecule-1-and-cluster-of-differentiation-146-levels-in-patients-with-type-2-diabetes-with-complications
#3
F Sinem Hocaoglu-Emre, Devrim Saribal, Guven Yenmis, Guvenc Guvenen
BACKGROUND: Type 2 diabetes mellitus (T2DM) is a multisystemic, chronic disease accompanied by microvascular complications involving various complicated mechanisms. Intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and cluster of differentiation-146 (CD146) are mainly expressed by endothelial cells, and facilitate the adhesion and transmigration of immune cells, leading to inflammation. In the present study, we evaluated the levels of soluble adhesion molecules in patients with microvascular complications of T2DM...
March 2017: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/28344829/systemic-angiopoietin-1-2-dysregulation-following-cardiopulmonary-bypass-in-adults
#4
Emmanuel Charbonney, Elizabeth Wilcox, Yuexin Shan, Pablo Perez d'Empaire, Abhijit Duggal, Gordon D Rubenfeld, Conrad Liles, Claudia Dos Santos
AIM: Vascular leakage following cardiopulmonary bypass contributes to morbidity. Angiopoietin-1 and -2 are biomarkers of endothelial dysfunction. Our aim was to characterize Ang-1 and -2 association with clinical characteristics and outcomes. METHODS: Observational cohort study measuring Ang-1/-2 with a panel of cytokines in adults undergoing cardiopulmonary bypass. RESULTS: Ang-2 levels increased immediately postop whereas Ang-1 levels decreased over time...
March 2017: Future Science OA
https://www.readbyqxmd.com/read/28344828/lc-ms-ms-assay-for-quantitation-of-enalapril-and-enalaprilat-in-plasma-for-bioequivalence-study-in-indian-subjects
#5
Dhiman Halder, Shubhasis Dan, Murari Mohun Pal, Easha Biswas, Nilendra Chatterjee, Pradipta Sarkar, Umesh Chandra Halder, Tapan Kumar Pal
BACKGROUND: Enalapril (EPL) is an angiotensin-converting enzyme inhibitor for the treatment of hypertension and chronic heart failure. Enalaprilat (EPLT) is an active metabolite that contributes to the overall activity of EPL. AIM: To quantitate EPL along with its metabolite EPLT using LC-MS/MS, a bioanalytical method was developed and validated with tolbutamide in human plasma using a protein precipitation technique. RESULTS: The sensitive and selective method has an LLOQ of 1 ng/ml with a linearity range of 1-500 ng/ml for both EPL and EPLT using 300 µl of plasma without any matrix effect...
March 2017: Future Science OA
https://www.readbyqxmd.com/read/28344754/role-of-angiotensin-converting-enzyme-and-angiotensinogen-gene-polymorphisms-in-angiotensin-converting-enzyme-inhibitor-mediated-antiproteinuric-action-in-type-2-diabetic-nephropathy-patients
#6
Neerja Aggarwal, Pawan Kumar Kare, Parul Varshney, Om Prakash Kalra, Sri Venkata Madhu, Basu Dev Banerjee, Anil Yadav, Alpana Raizada, Ashok Kumar Tripathi
AIM: To investigate the role of genetic variants of angiotensin converting enzyme (ACE) and angiotensinogen (AGT) genes in the antiproteinuric efficacy of ACE inhibitor therapy in diabetic nephropathy (DN) patients. METHODS: In the present study, 270 type 2 diabetes mellitus patients with nephropathy were enrolled and treated with ACE inhibitor (ramipril) and followed at 6 mo for renal function and albumin excretion by estimating serum creatinine, end stage renal disease, and albumin/creatinine ratio (ACR) in urine...
March 15, 2017: World Journal of Diabetes
https://www.readbyqxmd.com/read/28344559/cyclooxygenase-2-inhibition-limits-angiotensin-ii-induced-dna-oxidation-and-protein-nitration-in-humans
#7
Vincent Pialoux, Marc J Poulin, Brenda R Hemmelgarn, Daniel A Muruve, Erica N Chirico, Camille Faes, Darlene Y Sola, Sofia B Ahmed
Compared to other cyclooxygenase-2 inhibitors, celecoxib is associated with a lower cardiovascular risk, though the mechanism remains unclear. Angiotensin II is an important mediator of oxidative stress in the pathophysiology of vascular disease. Cyclooxygenase-2 may modify the effects of angiotensin II though this has never been studied in humans. The purpose of the study was to test the effects of selective cyclooxygenase-2 inhibition on plasma measures of oxidative stress, the vasoconstrictor endothelin-1, and nitric oxide metabolites, both at baseline and in respose to Angiotensin II challenge in healthy humans...
2017: Frontiers in Physiology
https://www.readbyqxmd.com/read/28344416/one-year-outcomes-of-acute-decompensated-systolic-heart-failure-in-taiwan-lessons-from-tsoc-hfref-registry
#8
Hung-Yu Chang, Chun-Chieh Wang, Yen-Wen Wu, Pao-Hsien Chu, Chih-Cheng Wu, Chih-Hsin Hsu, Ming-Shien Wen, Wen-Chol Voon, Wei-Shiang Lin, Jin-Long Huang, Shyh-Ming Chen, Ning-I Yang, Heng-Chia Chang, Kuan-Cheng Chang, Shih-Hsien Sung, Kou-Gi Shyu, Jiunn-Lee Lin, Guang-Yuan Mar, Kuei-Chuan Chan, Jen-Yuan Kuo, Ji-Hung Wang, Zhih-Cherng Chen, Wei-Kung Tseng, Wen-Jin Cherng, Wei-Hsian Yin
BACKGROUND: Heart failure (HF) is a global health problem. The Taiwan Society of Cardiology-Heart Failure with reduced Ejection Fraction (TSOC-HFrEF) registry was a multicenter, observational survey of patients admitted with HFrEF in Taiwan. The aim of this study was to report the one-year outcome in this large-cohort of hospitalized patients presenting with acute decompensated HFrEF. METHODS: Patients hospitalized for acute HFrEF were recruited in 21 hospitals in Taiwan...
March 2017: Acta Cardiologica Sinica
https://www.readbyqxmd.com/read/28344049/-serum-potassium-levels-and-long-term-mortality-in-the-elderly-with-hypertension
#9
M Heras Benito, M J Fernández-Reyes, M T Guerrero Díaz, A Muñoz Pascual
There is increasing evidence that small variations within the normal range (3.5-5mEq/L) of potassium are associated with mortality. OBJECTIVE: To determine whether there is an association between serum potassium level (sK) and mortality in a cohort of elderly hypertensive patients. PATIENTS AND METHODS: A retrospective, observational study was conducted on patients who had sK levels available in a period of clinical stability during their recruitment between January and April 2006 and followed-up for 10 years...
March 23, 2017: Hipertensión y Riesgo Vascular
https://www.readbyqxmd.com/read/28341271/obesity-and-kidney-disease-from-population-to%C3%A2-basic-science-and-the-search-for-new-therapeutic%C3%A2-targets
#10
REVIEW
Adam Whaley-Connell, James R Sowers
The global burden of kidney disease is increasing strikingly in parallel with increases in obesity and diabetes. Indeed, chronic kidney disease (CKD) and end-stage renal disease (ESRD) coupled with comorbidities such as obesity, diabetes, and hypertension cost the health care system hundreds of billions of dollars in the US alone. The progression to ESRD in patients with obesity and diabetes continues despite widespread use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) along with aggressive blood pressure and glycemic control in these high-risk populations...
March 21, 2017: Kidney International
https://www.readbyqxmd.com/read/28341094/association-between-exposure-to-angiotensin-converting-enzyme-inhibitors-and-angiotensin-receptor-blockers-prior-to-septic-shock-and-acute-kidney-injury
#11
B Suberviola, E Rodrigo, A González-Castro, M Serrano, M Heras, Á Castellanos-Ortega
OBJECTIVE: To evaluate the association between angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) use prior to a septic shock episode and the development, prognosis and long-term recovery from acute kidney injury (AKI). DESIGN: A single-centre, prospective observational study was carried out between September 2005 and August 2010. SCOPE: Patients admitted to the ICU of a third level hospital. PATIENTS: A total of 386 septic shock patients were studied...
January 2017: Medicina Intensiva
https://www.readbyqxmd.com/read/28340535/continuation-of-renin-angiotensin-aldosterone-inhibitors-does-not-impact-renal-function-among-patients-undergoing-percutaneous-nephrolithotomy
#12
Nishant D Patel, Benjamin R Cohen, Shubha De, Ganesh Kartha, Ina Li, Carl Sarkissian, Juan Camilo Calle, Manoj Monga
OBJECTIVE:   In the perioperative period, renin-angiotensin-aldosterone system (RAAS) inhibitors may result in cardiovascular and renal functional changes. We sought to determine the acute and chronic renal functional and blood pressure effects of continuing or withdrawing angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) after PCNL. MATERIALS AND METHODS:   This was a retrospective review of all patients undergoing PCNL at our institution from 2002-2013...
March 24, 2017: Journal of Endourology
https://www.readbyqxmd.com/read/28339659/the-use-of-guideline-recommended-beta-blocker-therapy-in-primary-prevention-implantable-cardioverter-defibrillator-patients-insight-from-danish-nationwide-registers
#13
Anne-Christine Ruwald, Gunnar Hilmar Gislason, Michael Vinther, Jens Brock Johansen, Jens Cosedis Nielsen, Helen Høgh Petersen, Christian Torp-Pedersen, Sam Riahi, Christian Jøns
Aims: We aimed to examine the use of guideline recommended beta-blocker therapy prior to and after primary prevention implantable cardioverter defibrillator (ICD) implantation in a 'real-life' setting. Methods and results: From the Danish Pacemaker and ICD Registry we identified all 1st-time primary prevention ICD and cardiac resynchronization therapy defibrillator (CRT-D) implantations in Denmark from 2007-12 (n = 2935). Use of beta-blocker, type and dose was acquired through the Danish Prescription Registry...
February 20, 2017: Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology
https://www.readbyqxmd.com/read/28338973/inflammation-autoimmunity-and-hypertension-the-essential-role-of-tissue-transglutaminase
#14
Chen Liu, Rodney E Kellems, Yang Xia
Inflammatory cytokines cause hypertension when introduced into animals. Additional evidence indicates that cytokines induce the production of autoantibodies that activate the AT1 angiotensin receptor (AT1R). Extensive evidence shows that these autoantibodies, termed AT1-AA, contribute to hypertension. We review here recent studies showing that cytokine-induced hypertension and AT1-AA production require the ubiquitous enzyme, tissue transglutaminase (TG2). We consider 3 mechanisms by which TG2 may contribute to hypertension...
March 13, 2017: American Journal of Hypertension
https://www.readbyqxmd.com/read/28338503/efficacy-and-safety-of-crystalline-valsartan-sacubitril-lcz696-compared-to-placebo-and-combinations-of-free-valsartan-and-sacubitril-in-patients-with-systolic-hypertension-the-ratio-study
#15
Joseph L Izzo, Dion H Zappe, Yan Jia, Kudsia Hafeez, Jack Zhang
We compared the systolic blood pressure-lowering efficacy and safety of crystalline valsartan/sacubitril (LCZ696, an angiotensin receptor blocker-neprilysin inhibitor) 400 mg daily against valsartan (320 mg once daily) alone or co-administered with placebo or increasing doses of free sacubitril (50, 100, 200, or 400 mg once daily) in order to identify the optimal antihypertensive combination dose. This multicenter, double-blinded, 7-arm parallel-group study recruited patients with mild-to-moderate systolic hypertension (office systolic BP 150-179 mmHg)...
March 23, 2017: Journal of Cardiovascular Pharmacology
https://www.readbyqxmd.com/read/28338370/the-potential-of-stimulating-nitric-oxide-formation-in-the-treatment-of-hypertension
#16
Lucas C Pinheiro, Jose E Tanus-Santos, Michele M Castro
Hypertension is a leading cause of morbidity and mortality worldwide. A major pathophysiological factor contributing to hypertension is reduced nitric oxide (NO) bioavailability. Strategies to address this pathophysiological mechanism could offer significant advantages. Areas covered: In this review we aimed at examining a variety of drugs (statins, beta-adrenergic receptor blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, angiotensin II type-1 receptor blockers) used to treat hypertension and other cardiovascular diseases, particularly with respect to their potential of increasing NO bioavailability and activity in the cardiovascular system...
March 24, 2017: Expert Opinion on Therapeutic Targets
https://www.readbyqxmd.com/read/28337307/effects-of-microrna-29a-on-retinopathy-of-prematurity-by-targeting-agt-in-a-mouse-model
#17
Xin-Ke Chen, Li-Juan Ouyang, Zheng-Qin Yin, Yuan-You Xia, Xiu-Rong Chen, Hui Shi, Yan Xiong, Lian-Hong Pi
BACKGROUND: This study aimed to explore the effects of microRNA-29a (miR-29a) on retinopathy of prematurity (ROP) by targeting angiotensinogen (AGT) expression in a mouse model. METHODS: Ninety-six C57BL/6J mice were selected and divided into the normal control group (n = 12) and the oxygen-induced retinopathy (OIR) group (n = 84). All the mice in the OIR group were assigned to the following seven groups (12 mice in each group): the blank, miR-29a mimics, miR-29a inhibitors, empty plasmid, miR-29a mimics + si-AGT, miR-29a inhibitors + si-AGT and si-AGT groups...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28337260/mir-590-3p-mediates-the-protective-effect-of-curcumin-on-injured-endothelial-cells-induced-by-angiotensin-ii
#18
Tian Wu, Yuanyuan Xiang, Yu Lv, Dai Li, Lijin Yu, Ren Guo
Curcumin (Cur) has multiple pharmacological effects including antitumor, anti-inflammatory, antioxidant and cardiovascular protective effects. This research aims to further explore whether the cardiovascular protective effects of Cur are mediated by the miR-590-3p/CD40 pathway. Endothelial cells (ECs) were cultivated with 10(-7) mol/L angiotensin II (Ang II) to establish a damage model. Real-time PCR was used to determine the expression of CD40 and eNOS mRNA on ECs. The protein expressions of CD40 and eNOS were detected by Western blot analysis...
2017: American Journal of Translational Research
https://www.readbyqxmd.com/read/28337024/angiotensin-ii-promotes-the-anticoagulant-effects-of-rivaroxaban-via-angiotensin-type-2-receptor-signaling-in-mice
#19
Dan Yang, Junjie Shao, Ruifeng Hu, Haimei Chen, Ping Xie, Chang Liu
Rivaroxaban is an oral direct factor Xa inhibitor approved for the treatment of stroke and systemic thromboembolism in patients with non-valvular atrial fibrillation. Despite its efficacy, rivaroxaban therapy results in adverse effects and complications, such as bleeding. Angiotensin II (AngII) is implicated in many cardiovascular conditions, such as hypertension and heart failure. In this study, we investigate whether AngII influences anticoagulant effects of rivaroxaban by using an experimental mouse model with type 2 diabetes mellitus and advanced glycation end product (AGE)-exposed human umbilical vein endothelial cells (HUVECs)...
March 23, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28336948/plasminogen-activator-inhibitor-1-protects-mice-against-cardiac-fibrosis-by-inhibiting-urokinase-type-plasminogen-activator-mediated-plasminogen-activation
#20
Kamlesh K Gupta, Deborah L Donahue, Mayra J Sandoval-Cooper, Francis J Castellino, Victoria A Ploplis
Plasminogen activator inhibitor-1 (PAI-1) is known to protect mice against cardiac fibrosis. It has been speculated that PAI-1 may regulate cardiac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimately plasmin (Pm) generation. However, the in vivo role of PAI-1 in inactivating uPA and limiting the generation of Pm during cardiac fibrosis remains to be established. The objective of this study was to determine if the cardioprotective effect of PAI-1 is mediated through its ability to directly regulate urokinase -mediated activation of plasminogen (Pg)...
March 23, 2017: Scientific Reports
keyword
keyword
22787
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"